Combination drug therapy for glycolipid storage diseases
US6495570B2 · kind B2 · utility
27Cited by
6References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 2001 |
| Grant date | Dec 17, 2002 |
| Priority date | — |
| Expiry date | May 17, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel combination drug therapy is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of both a N-alkyl derivative of deoxynojirimycin (DNJ) and a glucocerebrosidase enzyme to alleviate or inhibit the glycolipid storage disease. The alkyl group has from about two to about 20 carbon atoms and preferably is butyl, nonyl or decyl.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.